Trial Profile

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 23 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ARX 788 (Primary)
Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Therapeutic Use
Acronyms ACE-Breast-3
Sponsors Ambrx

Most Recent Events

20 Jan 2025 Planned End Date changed from 1 Dec 2026 to 1 Jun 2027.
20 Jan 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Dec 2026.
10 Dec 2024 Trial design presented at the 47th Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com